FTRE vs ICLR vs NTRB Stock Comparison

Fortrea Holdings, Icon and NutriBand Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (TMO) Create a free account to keep reading and compare up to 10 companies.
FTRE Fortrea Holdings Inc.
$23.14 +17.2% 1M +121.6% 1Y
Market cap
$2.01B
P/E
–
Revenue (TTM)
$2.67B
Div. yield
–
Contract Research Healthcare
2 wins
ICLR Icon Plc
$215.48 +26.5% 1M +29.8% 1Y
Market cap
$16.51B
P/E
36.8x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
5 wins
NTRB NutriBand Inc.
$6.64 -19.5% 1M -4.2% 1Y
Market cap
$76.70M
P/E
–
Revenue (TTM)
$1.62M
Div. yield
–
Generic Drugs Healthcare
3 wins

Head to Head

10 decided of 12

Icon leads on 5 of the 12 questions below (Icon 5, NutriBand 3, Fortrea Holdings 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionFTREICLRNTRBLeader
Larger companyMarket capitalisation $2.01B $16.51B $76.70M ICLR
Cheaper on earningsLower P/E, profitable companies only -29.2x 36.8x -11.0x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.6x 21.0x 4.0x NTRB
Faster revenue growthRevenue growth, trailing twelve months -3.4% +1.8% -37.3% ICLR
More profitableNet margin, trailing twelve months -2.6% 5.4% -430.4% ICLR
Better return on capitalReturn on invested capital 0.8% 4.7% — ICLR
Less leveragedLower net debt / EBITDA 9.1x 2.3x 0.5x NTRB
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +121.6% +29.8% -4.2% FTRE
Better 5-year returnAnnualised price return, 5 years — -5.6%/yr +4.3%/yr NTRB
Less volatileAnnualised volatility, 1 year 71.4% 75.0% 79.1% FTRE
Higher overall scoreMean of the five percentile scores vs peers 53/100 81/100 51/100 ICLR

Percentile Scorecard

FTREICLRNTRB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisFTREICLRNTRB
Valuation 90 #2 of 11 100 #1 of 11 56 #278 of 624
Growth 60 #5 of 11 70 #4 of 11 43 #344 of 601
Profitability 60 #5 of 11 80 #3 of 11 36 #346 of 541
Financial Health 0 #13 of 13 75 #4 of 13 68 #207 of 647
Shareholder Returns – – –
Overall 53 81 51
  • FTRE ranked among 13 companies in Pharma Services
  • ICLR ranked among 13 companies in Pharma Services
  • NTRB ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodFTREICLRNTRBSPY
1 month +17.2%+26.5%-19.5% +0.7%
3 months +21.3%+30.2%+128.2% +3.7%
6 months +101.2%+82.1%+71.6% +7.1%
Year to date +34.1%+18.3%+46.3% +12.8%
1 year +121.6%+29.8%-4.2% +11.9%
3 years -15.2%-9.5%+210.3% +85.2%
3 years, per year -5.4%-3.3%+45.9% +22.8%
5 years —-24.9%+23.6% +67.6%
5 years, per year —-5.6%+4.3% +10.9%
10 years —+168.3%— +262.0%
10 years, per year —+10.4%— +13.7%

Risk

MeasureFTREICLRNTRBSPY
Volatility, 1Y 71.4%75.0%79.1% 12.7%
Downside volatility, 1Y 65.5%87.7%73.9% 12.6%
Beta vs S&P 500, 1Y 2.041.471.03 1.00
Return / volatility, 1Y 1.700.40-0.05 0.94
Max drawdown, 5Y -89.9%-76.9%-77.7% -25.4%
From 52-week high -10.6%0.0%-26.1% -1.2%
52-week high $25.88$215.48$8.99 $779.14
52-week low $8.87$80.08$2.81 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleFTREICLRNTRB
P/E now vs peer median -32.2xmedian 36.6x 37.7xmedian 36.6x -11.6xmedian 17.8x
P/S now vs peer median 0.8xmedian 2.6x 2.0xmedian 2.6x 49.9xmedian 9.1x
EV/EBITDA now vs peer median 33.5xmedian 31.1x 17.4xmedian 31.1x -11.2xmedian 15.0x
P/FCF now vs peer median 13.2xmedian 21.8x 19.3xmedian 21.8x -22.2xmedian 21.7x
P/B now vs peer median 4.2xmedian 3.1x 1.8xmedian 3.1x 15.1xmedian 2.2x
PEG now vs peer median 0.53median 2.05 -15.86median 2.05 -14.12median 0.35

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsFTREICLRNTRB
Revenue $2.67B $8.23B $1.62M
Gross profit $533.40M $1.93B $536.12K
Operating income $12.80M $718.25M -$7.05M
Net income -$68.70M $448.66M -$6.96M
Free cash flow $169.00M $857.06M -$3.63M
R&D – – $1.21M
EPS (diluted) $-0.68 $5.68 $-0.57
Cash & equivalents $220.60M $808.98M $3.42M
Total debt $1.06B $3.38B $647.66K
Shares (diluted) 101.20M 78.97M 12.16M
Enterprise value $1.30B $13.28B $59.39M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricFTREICLRNTRB
P/E -32.2x 37.7x -11.6x
P/FCF 13.2x 19.3x -22.2x
P/Operating cash flow 11.1x 16.1x -22.2x
P/S 0.8x 2.0x 49.9x
P/B 4.2x 1.8x 15.1x
P/Tangible book -56.2x 2.7x 15.6x
EV/EBITDA 33.5x 17.4x -11.2x
EV/EBIT 239.7x 26.5x -11.0x
EV/Revenue 1.2x 2.3x 47.9x
EV/FCF 18.2x 22.2x -21.3x
EV/Operating cash flow 15.2x 18.6x -21.3x
PEG (3Y EPS CAGR) 0.53 -15.86 -14.12

Growth

14 metrics
MetricFTREICLRNTRB
Revenue growth (1Y) -3.4% 1.8% -37.3%
Revenue CAGR (3Y) 0.4% 0.9% -10.8%
Gross profit growth (1Y) 3.9% -13.4% -39.5%
Gross profit CAGR (3Y) -8.5% -6.5% -16.5%
Operating income growth (1Y) 101.4% 53.9% 32.3%
Operating income CAGR (3Y) -43.3% -7.0% -15.3%
Net income growth (1Y) 93.2% 55.9% 32.2%
Net income CAGR (3Y) -47.8% -4.4% -14.8%
EPS growth (1Y) 93.9% 30.1% 80.0%
EPS CAGR (3Y) -60.7% -2.4% 0.8%
Operating cash flow growth (1Y) 13,353% -9.9% 25.9%
Operating cash flow CAGR (3Y) 5.2% 15.8% -5.7%
Free cash flow growth (1Y) 1,400% -11.1% 26.6%
Free cash flow CAGR (3Y) 10.8% 18.4% -5.5%

Profitability

14 metrics
MetricFTREICLRNTRB
Gross margin 20.0% 23.4% 33.1%
EBITDA margin 3.4% 13.3% -426.5%
Operating margin 0.5% 8.7% -435.6%
Pretax margin -2.0% 6.3% -430.4%
Net margin -2.6% 5.4% -430.4%
FCF margin 6.3% 10.4% -224.5%
Operating cash flow margin 7.6% 12.5% -224.5%
Return on equity -13.0% 7.6% -123.0%
Return on assets -2.5% 4.3% -105.6%
Return on invested capital 0.8% 4.7% –
Return on capital employed 0.7% 5.3% -123.9%
Asset turnover 1.0x 0.5x 0.2x
Cash conversion (OCF / net income) -2.9x 2.3x 0.5x
Stock comp / revenue 1.9% 1.1% 204.1%

Financial Health

11 metrics
MetricFTREICLRNTRB
Debt / assets 38.5% 20.8% 2.4%
Debt / equity 2.0x 0.4x 0.0x
Net debt / EBITDA 9.1x 2.3x 0.5x
Debt / FCF 6.2x 3.9x 0.0x
Liabilities / assets 80.6% 43.8% 15.3%
Equity / assets 19.4% 56.2% 84.7%
Interest coverage – 3.4x -339.3x
Current ratio 1.0x 1.3x 4.2x
Quick ratio 0.9x 0.9x 3.8x
Cash ratio 0.2x 0.3x 3.8x
Altman Z-score 0.86 2.28 36.48

Shareholder Returns

7 metrics
MetricFTREICLRNTRB
Dividend yield – – –
Net buyback yield – 2.3% –
Shareholder yield – 2.3% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusFTREICLRNTRB
Forward P/E 28.6xFY2026 21.0xFY2026 4.0xFY2026
EPS, next fiscal year $0.81FY2026 $10.25FY2026 $1.65FY2026
EPS growth, next FY +88.4%FY2026 -18.2%FY2026 –
EPS growth, the year after +22.2% +22.2% +112.1%
Revenue, next fiscal year $2.77BFY2026 $8.52BFY2026 $90.32MFY2026
Revenue growth, next FY +1.7%FY2026 +3.2%FY2026 +4,334.5%FY2026
Revenue growth, the year after -3.4% -3.2% +109.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersFTREICLRNTRB
Held by institutions 100.0% 100.0% –
Institutions holding 330 423 –
Change in shares held, QoQ -0.2% +5.5% –
Institutions buying 140 234 –
Institutions selling 108 138 –
Buyers to sellers 1.30 1.70 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

FTREICLRNTRB
FTRE 1.00 0.47 0.16
ICLR 0.47 1.00 0.17
NTRB 0.16 0.17 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, FTRE, ICLR and NTRB?

Icon (ICLR) is the largest by market capitalisation: Fortrea Holdings (FTRE) $2.01B, Icon (ICLR) $16.51B, NutriBand (NTRB) $76.70M.

Which company is growing faster?

Icon (ICLR) grew revenue fastest over the trailing twelve months: Fortrea Holdings (FTRE) -3.4%, Icon (ICLR) +1.8%, NutriBand (NTRB) -37.3%.

Which company is more profitable?

Icon (ICLR) has the highest net margin (Fortrea Holdings (FTRE) -2.6%, Icon (ICLR) 5.4%, NutriBand (NTRB) -430.4%). On return on invested capital, Icon (ICLR) leads (Fortrea Holdings (FTRE) 0.8%, Icon (ICLR) 4.7%).

Which stock has performed better?

Over the past year Fortrea Holdings (FTRE) returned the most: Fortrea Holdings (FTRE) +121.6%, Icon (ICLR) +29.8%, NutriBand (NTRB) -4.2%. Over five years, NutriBand (NTRB) compounded fastest (Icon (ICLR) -5.6%/yr, NutriBand (NTRB) +4.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Fortrea Holdings (FTRE) has been the steadiest (Fortrea Holdings (FTRE) 71.4%, Icon (ICLR) 75.0%, NutriBand (NTRB) 79.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, FTRE, ICLR and NTRB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Icon (ICLR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.